Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
US10849893B2 · kind B2 · utility
1Cited by
0References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2019 |
| Grant date | Dec 1, 2020 |
| Priority date | — |
| Expiry date | Dec 16, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.